Vancomycin is a common antibiotic used to treat gram-positive bacterial infections. It targets a key building block of the bacterial cell wall called Lipid II, but it can’t reach this lipid in ...

iSydney Institute for Infectious Diseases, School of Public Health, Faculty of Medicine The University of Sydney, Sydney, Australia jSchool of Women and Children's Health, The University of NSW School ...

Objective This study aimed to determine the prevalence and antimicrobial susceptibility profile of non-fermenting Gram-negative bacilli (NFGNB) isolated from clinical samples in a tertiary care ...

Seven days of antibiotics was noninferior to 14 days for treating Gram-negative bloodstream infections, supporting shorter courses in hospitalized patients. The optimal duration of antibiotic therapy ...

• Require X (hemin) and/or V (nicotinamide adenine dinucleotide) factors for growth • Responsible for 0.5–1% of all cases of IE • Haemophilus aphrophilus is the most common species responsible for IE ...

After completing a degree in Film, Television, and Cultural Studies at Manchester Metropolitan University, I decided to pursue my love of writing and video games by entering the world of video game ...

Cerebrospinal fluid proteome during chemotherapy for childhood leukemia: Identifying pathways associated with treatment and system toxicity. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Uptake of new gram-negative antibiotics remains lower for agents approved within the past decade than for older agents such as piperacillin-tazobactam, but their use has become more common than ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Infections complicate burn wound care, especially with the rise of antimicrobial ...

Using its proprietary FBDD platform, Blacksmith discovered FG-2101, the prodrug form of FG-960, the first known non-hydroxamate LpxC inhibitor that exerted activity against LpxC at the nanomolar range ...

Centauri Therapeutics Ltd. has selected its first clinical candidate in the ABX-01 program to treat gram-negative bacterial lung infections. Based on the company’s Alphamer platform, the ...